February 4, 2019 7:58am

Indications are subdued; news is weak, where are insider’s BUYs – a sentiment indicator?

Three (3) positive closes in a row in and following January’s 22 sessions, when there were 13 positive, 1 neutral, 1 holiday and 7 negative closes

News: UniQure (QURE) had Monday morning news of treating its first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. AMT-061 has been granted Breakthrough Therapy Designation by the U.S. FDA and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency – Maintaining BUY

Pre-open indications: 1 BUY, 2 SELLs, 1 HOLD and 3 trades


Skim if you can trim, buy if it will fly and sell if compelled!

Members only. Please login.